Posted inCritical Care news
Targeting Tissue Perfusion and Lower MAP in Septic Shock Did Not Improve 30‑Day Perfusion-Free Survival: Results from the TARTARE-2S Randomized Trial
In the TARTARE-2S trial, a tissue-perfusion–guided resuscitation strategy that permitted lower MAP (50–65 mm Hg) did not increase days alive with normalized lactate and without vasopressors at 30 days versus standard-of-care MAP-guided treatment in septic shock.